There’s a version of IVF that most people don’t encounter until they’ve already had a failed cycle. Or two. Then someone mentions PGT-A, and suddenly a lot of things start making sense retrospectively.
That sequencing is a problem. PGT-A, preimplantation genetic testing for aneuploidy, is still treated by many clinics as something you add after failure, a response to things going wrong rather than a tool for preventing them. For certain patient profiles, that approach costs people cycles, money, and months of emotional toll that didn’t need to happen. The technology exists. The evidence exists. The question is whether the conversation is happening early enough.
This is what PGT-A actually does, who it genuinely helps, what the data shows, and where its real limits are. Because there are limits, and anyone selling you PGT-A without mentioning them is prioritising revenue over honesty.
The Problem It’s Solving
The single biggest reason IVF cycles fail, across all age groups, is chromosomal abnormality in the embryo. An embryo can look perfect under the microscope, develop to blastocyst on schedule, and still carry a chromosomal error that makes implantation biologically impossible. It either fails to implant entirely or implants and miscarries, usually in the first trimester.
This is not rare. Chromosomal abnormality testing in IVF consistently shows that a substantial proportion of embryos, even from young patients, are aneuploid. In women under 35, roughly 30-40% of blastocysts carry chromosomal errors. By 40, that figure is 60-70%. Above 42, it can exceed 80%.
The embryologist cannot see this. No morphological grading system, however refined, reliably distinguishes a chromosomally normal embryo from an abnormal one. They look identical. Grading tells you about cell organisation and development speed. It tells you nothing about the chromosomes.
PGT-A addresses this by biopsying a small number of cells from each blastocyst and analysing all 23 chromosome pairs before transfer. The result is a ranked list: euploid (chromosomally normal), aneuploid (abnormal), or mosaic (mixed). Only euploid embryos are transferred.
What the Testing Involves
Embryo genetic screening before IVF follows the standard IVF process: stimulation, retrieval, fertilisation, embryo culture. The PGT-A step happens on day 5 or 6 when embryos reach blastocyst stage.
An embryologist performs a trophectoderm biopsy. A laser creates a small opening in the outer cell layer of the blastocyst, and 5-8 cells are removed. These cells are from the trophectoderm, the portion that becomes placental tissue, not the embryo itself. When done by a trained embryologist, the procedure does not damage the embryo.
The cells go to a genetics laboratory for Next Generation Sequencing (NGS), the current gold standard for chromosomal analysis. Results take 10-14 days. Embryos are vitrified and stored during this period. Transfer happens in a subsequent frozen cycle.
This is why PGT-A always involves a freeze-all strategy. There is no fresh transfer after genetic screening. That adds time to the treatment journey, and patients should know this before they consent.
Four Scenarios That Show When PGT-A Changes Everything
Consider four hypothetical clinical profiles that illustrate when PGT-A changes the decision.
The first: a 39-year-old on her second IVF cycle. Her first cycle produced three morphologically high-graded blastocysts. One transferred fresh: failed to implant. A second in FET: chemical pregnancy, no heartbeat. Before transferring the third and final embryo, PGT-A is recommended. Testing reveals it is aneuploid. It would almost certainly have failed too. The conversation shifts entirely: a new stimulation cycle is needed, with PGT-A from the start. That’s difficult information. But it’s accurate information, and accurate is far more useful than two more failed transfers a test could have prevented.
The second: a 31-year-old with three first-trimester miscarriages, comprehensive recurrent miscarriage investigation returning normal across all standard parameters. Losses labelled unexplained. In a profile like this, chromosomal abnormality in the embryo is the most statistically common cause of first-trimester loss, and the standard recurrent miscarriage workup doesn’t test for it because it can’t, until there’s an embryo to test. PGT-A for recurrent miscarriage in this profile is not a speculative add-on. It’s the most logical diagnostic step not yet taken.
The third: a hypothetical patient with two failed FETs using morphologically excellent blastocysts, normal uterine cavity, adequate endometrial thickness, and a confirmed correct ERA window. Before investigating obscure immunological explanations, PGT-A is run on the remaining stored embryos. Two are aneuploid. One is euploid. The euploid embryo transfers successfully. The previous failures were not about the uterus. They were about chromosomes nobody had checked.
The fourth: a 44-year-old who retrieves five eggs across two stimulation cycles, with two reaching blastocyst. PGT-A shows both aneuploid. Nothing to transfer. Devastating, but accurate. The alternative, transferring both without testing and experiencing two more failures or miscarriages, would take another four to six months and be no less devastating at the end. PGT-A did not cause this outcome. It revealed what the biology was already determining.
Who Should Seriously Consider It
PGT-A is not the right call for every IVF patient. The honest breakdown:
Women over 37: The correlation between maternal age and embryo aneuploidy is the most reliable predictive variable in reproductive medicine. Above 37, the proportion of chromosomally abnormal embryos rises steeply enough that PGT-A materially changes transfer strategy. Above 40, it’s very difficult to argue against it on clinical grounds.
Patients with recurrent implantation failure: Two or more failed transfers with morphologically good blastocysts are a strong signal that chromosomal factors may be contributing. Before investigating the uterine environment further, knowing whether the embryos were chromosomally normal is the logical first question.
Patients with recurrent pregnancy loss: PGT-A for recurrent miscarriage has genuine evidence behind it. When first-trimester losses are recurring, transferring only euploid embryos directly addresses the most statistically likely cause.
Couples with known chromosomal translocations: When either partner carries a balanced translocation, the proportion of unbalanced embryos can be very high. PGT-A identifies viable embryos before transfer rather than discovering the problem through repeated failure.
PGT-A has weaker justification for women under 35 who are on their first IVF attempt, have a good ovarian reserve, and no history of implantation failure or loss. The aneuploidy rate is lower, cumulative success without PGT-A is already reasonable, and the freeze-all requirement adds time without meaningfully changing the eventual outcome. Clinics that universally recommend PGT-A, regardless of age or history, ignore the evidence. They’re following the margin.
What the Success Rate Data Actually Shows
The PGT-A success rate data requires careful reading, because this is also where the technology has been most aggressively oversold.
What is clearly supported: transferring a confirmed euploid embryo results in significantly higher implantation and live birth rates per transfer than transferring an unscreened embryo. In women over 38, the per-transfer live birth rate with a euploid embryo runs roughly 40-55%, compared to 20-30% for an unscreened transfer in the same age group. Per transfer, that’s a real difference.
What is more complicated is cumulative live birth rates across a full treatment course. Several large studies, including a randomised controlled trial in the New England Journal of Medicine found that when comparing PGT-A to no PGT-A across multiple transfers, cumulative outcomes were not consistently better, particularly in younger patients. Without PGT-A, patients transfer aneuploid embryos that fail, but they cycle through those failures faster and eventually reach the viable embryo. PGT-A identifies the right embryo first, but the freeze-all requirement and biopsy cycle add time.
The clinical implication: PGT-A improves the efficiency of the route. It reduces failed transfers, reduces miscarriages, and delivers information that biology would eventually reveal through trial and error, but faster and with less physical and emotional cost per outcome. For older patients and those with recurrent failure or loss, that efficiency has genuine clinical value. For young first-time IVF patients with a good prognosis, the case is legitimately less clear.
The thing most clinics don’t say clearly enough: PGT-A does not improve embryo quality. It identifies which embryos are likely viable. If all embryos from a retrieval are aneuploid, which is entirely possible in older patients, there is nothing to transfer. The test reveals the biology. It does not change it. That expectation should be set before testing begins, not after the results come back.
The Mosaic Embryo Issue
As PGT-A became widespread, mosaic embryos emerged as a clinical complexity that earlier protocols handled badly. A mosaic result means the biopsy shows a mix of normal and abnormal cells. Initial protocols discarded all mosaics. Current guidance from PGDIS and ESHRE is more nuanced: low-level mosaics (under 40% abnormal cells) may be considered for transfer in the absence of euploid embryos, with appropriate counselling, because a meaningful proportion of low-level mosaic transfers result in healthy pregnancies.
This is an active clinical debate, and it’s one where patient counselling quality varies significantly between centres. The right question for any clinic offering PGT-A: what is your protocol for mosaic embryos? “We never transfer mosaics” is outdated. “We transfer mosaics without specific counselling” is inadequate. The answer should reflect current guidance and include a genuine informed consent conversation about what a mosaic result means for that specific embryo and patient.
What PGT-A Costs in India
Preimplantation genetic testing cost in India is considerably lower than equivalent testing in the UK or US, which has made the technology accessible to a broader patient population than in most Western markets.
A realistic breakdown of what you’re actually paying for:
- Trophectoderm biopsy (per embryo or as cycle charge): typically ₹15,000-25,000
- NGS analysis at the genetics laboratory: ₹30,000-60,000 for the first embryo, reducing per-embryo for additional samples biopsied in the same batch
- Total PGT-A cost per cycle including biopsy and analysis for 3-5 embryos: ₹80,000-1,50,000 at most Indian centres
- Full IVF cycle with PGT-A included: typically ₹2,50,000-4,00,000 depending on medications, monitoring, and centre
For context, the same testing costs £2,000-£3,500 more in the UK and frequently exceeds $4,000 in the US. The preimplantation genetic testing cost in India represents genuinely excellent value for a complex genetic analysis.
At 9M Fertility, PGT-A testing in Hyderabad is costed transparently, and the recommendation is made on clinical grounds specific to your age, history, and embryo profile, not applied as a premium default.
The Conversation Worth Having Before Your Next Transfer
If you’ve had more than one failed transfer with morphologically excellent embryos, more than one first-trimester miscarriage, or you’re over 37 starting IVF, chromosomal abnormality testing should be a conversation your specialist initiates. If it hasn’t come up, ask directly for a specific answer about your profile rather than a general one about the technology.
The question isn’t just, “Would we do PGT-A?” It’s “given my age, ovarian reserve, and history, does the evidence suggest PGT-A changes my outcome, and by how much?” That’s a harder question. It deserves a specific answer.
PGT-A testing in Hyderabad at 9M Fertility sits within a treatment framework where the decision is based on your complete clinical picture. We don’t apply it universally, and we don’t withhold it from patients who would genuinely benefit. The goal is a recommendation that reflects what your situation actually calls for.
If you’ve been through failed cycles and want to understand whether chromosomally abnormal embryos may have been a factor, that consultation is where the answer starts. Bring your previous cycle records. The more clinical information available, the more precise the conversation.
Book a consultation at 9M Fertility.
→ Also read: IVF vs ICSI: Which Fertility Treatment Is Right for You?
→ Also read: ERA Test in IVF: How It Helps Find Your Perfect Embryo Transfer Window
